Paola Gazzaniga
Overview
Explore the profile of Paola Gazzaniga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicolazzo C, Frullanti E, Gazzaniga P, Palmieri M
Front Oncol
. 2024 Dec;
14:1519816.
PMID: 39659796
No abstract available.
2.
Magri V, Marino L, Del Giudice F, De Meo M, Siringo M, De Berardinis E, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457670
Non-muscle-invasive bladder cancer (NMIBC) prognosis varies significantly due to the biological and clinical heterogeneity. High-risk stage T1-G3, comprising 15-20% of NMIBCs, involves the lamina propria and is associated with higher...
3.
Del Giudice F, Vestri A, Fegatelli D, Husch T, Belsey J, Nair R, et al.
BJU Int
. 2024 Oct;
135(2):346-354.
PMID: 39397266
Background: A second transurethral resection of bladder tumour (Re-TURBT) is recommended by European Association of Urology (EAU) Guidelines on non-muscle-invasive bladder cancers (NMIBCs) due to the risk of understaging and/or...
4.
Magri V, De Renzi G, Marino L, De Meo M, Siringo M, Gelibter A, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612563
Evidence has been provided that circulating cancer-associated macrophage-like cell (CAM-L) numbers increase in response to chemotherapy, with an inverse trend compared to circulating tumor cells (CTCs). In the era of...
5.
Magri V, Marino L, De Renzi G, De Meo M, Salvatori F, Buccilli D, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397990
Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations...
6.
Nicolazzo C, Francescangeli F, Magri V, Giuliani A, Zeuner A, Gazzaniga P
Cancer Metastasis Rev
. 2023 Aug;
42(4):1201-1218.
PMID: 37540301
Some relevant emerging properties of intelligent systems are "adaptation to a changing environment," "reaction to unexpected situations," "capacity of problem solving," and "ability to communicate." Single cells have remarkable abilities...
7.
Magri V, Marino L, Nicolazzo C, Gradilone A, De Renzi G, De Meo M, et al.
Cells
. 2023 May;
12(8).
PMID: 37190081
Background: A large amount of evidence from clinical studies has demonstrated that circulating tumor cells are strong predictors of outcomes in many cancers. However, the clinical significance of CTC enumeration...
8.
Nicolazzo C, Magri V, Marino L, Belardinilli F, Di Nicolantonio F, De Renzi G, et al.
Front Oncol
. 2023 Apr;
13:1160673.
PMID: 37064137
Background: The term "neo- wild-type" refers to the switch to wild-type disease in plasma circulating tumor DNA (ctDNA) from originally mutant colorectal cancers. Consistently, the hypothesis to re-determine mutational status...
9.
Nicolazzo C, Gazzaniga P
Methods Mol Biol
. 2022 Jul;
2535:93-104.
PMID: 35867225
Liquid biopsies represent a valid alternative to conventional tissue biopsies, offering a real time molecular picture of tumors in a minimally invasive manner. Of the various circulating biomarkers available for...
10.
De Angelis M, Francescangeli F, Nicolazzo C, Xhelili E, La Torre F, Colace L, et al.
Front Oncol
. 2022 Jul;
12:869485.
PMID: 35837106
Metastasis is the primary cause of death in patients with colorectal cancer (CRC), urging the need for preclinical models that recapitulate the metastatic process at the individual patient level. We...